Bilomo | Kelleng | |||||
---|---|---|---|---|---|---|
1998 | 2017 | P-value | 2004 | 2018 | P-value | |
Gender of PWE | ||||||
Male: n (%) | 51 (54.8%) | 27 (44.3%) | 0.199 | 10 (52.6%) | 8 (50.0%) | 0.877 |
Female: n (%) | 42 (45.2%) | 34 (55.7%) | 9 (47.4%) | 8 (50.0%) | ||
Total: n (%) | 93 (100%) | 61 (100%) | 19 (100%) | 16 (100%) | ||
Age distribution of PWE: n (%) | ||||||
0–9 years | 3 (3.2%) | 1 (1.6%) | < 0.001 | 0 (0%) | 0 (0%) | 0.530 |
10–19 years | 56 (60.2%) | 12 (19.7%) | 6 (31.6%) | 2 (12.5%) | ||
20–29 years | 28 (30.1%) | 29 (47.5%) | 8 (42.1%) | 7 (43.8%) | ||
30–39 years | 6 (6.5%) | 15 (24.6%) | 4 (21.0%) | 4 (25.0%) | ||
40–49 years | 0 (0%) | 3 (4.9%) | 1 (5.3%) | 2 (12.5%) | ||
≥50 years | 0 (0%) | 1 (1.6%) | 0 (0%) | 1 (6.2%) | ||
Total | 93 (100%) | 61 (100%) | 19 (100%) | 16 (100%) | ||
Mean age of PWE ± SD years | 18.2 ± 5.7 | 24.9 ± 8.1 | P < 0.0001 | NA | 31.4 ± 15.4 | NA |
Age-specific prevalence: n (%) | ||||||
0–9 years | 3 (0.5%) | 1 (0.2%) | < 0.001 | 0 (0.0%) | 0 (0.0%) | 0.676 |
10–19 years | 56 (12.9%) | 12 (4.0%) | 6 (26.1%) | 2 (4.7%) | ||
20–29 years | 28 (11.5%) | 29 (17.1%) | 8 (30.8%) | 7 (30.4%) | ||
30–39 years | 6 (2.6%) | 15 (9.4%) | 4 (14.8%) | 4 (16.7%) | ||
40–49 years | 0 (0.0%) | 3 (3.5%) | 1 (5.0%) | 2 (11.8%) | ||
≥50 years | 0 (0.0%) | 1 (0.5%) | 0 (0.0%) | 1 (2.4%) | ||
Overall crude prevalence (%) | 93/1898 (4.9%) | 61/1321 (4.6%) | 0.695 | 19/181 (10.5%) | 16/204 (7.8%) | 0.357 |
Age and sex standardized prevalence rate | NA | 5.4% | NA | 13.5% | 9.3% | < 0.001 |
Age of onset of first seizure: n (%) | ||||||
Mean age at onset ± SD years | 12.7 ± 5.97 | 12.6 ± 4.1 | 0.909 | 14.7 ± 6.5 | 14.1 ± 7.7 | 0.804 |
0–2 years | 4 (4.3%) | 0 (0.0%) | 0.944 | NA | 0 (0.0%) | NA |
3–6 years | 9 (9.7%) | 4 (6.6%) | 0 (0.0%) | |||
7–12 years | 33 (35.5%) | 23 (37.7%) | 8 (50.0%) | |||
13–20 years | 41 (44.1%) | 26 (42.6%) | 7 (43.8%) | |||
≥21 years | 4 (4.3%) | 2 (3.3%) | 1 (6.3%) | |||
Not known | 2 (2.2%) | 6 (9.8%) | 0 (0.0%) | |||
Total | 93 (100.0%) | 61 (100.0%) | 16 (100.0%) | |||
Duration of epilepsy: n (%) | ||||||
Mean duration ± SD years | NA | 12.7 ± 8.8 yrs | NA | 8.7 ± 7.1 yrs | 17.4 ± 14.1 yrs | 0.036 |
0–1 year | NA | 5 (8.2%) | NA | 3 (15.8%) | 0 (0.0%) | 0.363 |
2–5 years | 10 (16.4%) | 4 (21.1%) | 1 (6.3%) | |||
6–10 years | 10 (16.4%) | 5 (26.3%) | 5 (31.3%) | |||
11–20 years | 18 (29.5%) | 6 (31.6%) | 6 (37.5%) | |||
> 20 years | 13 (21.3%) | 1 (5.3%) | 4 (25.0%) | |||
Not known | 5 (8.2%) | 0 (0.0%) | 0 (0.0%) | |||
Total | 61 (100.0%) | 19 (100.0%) | 16 (100.0%) |